Oral News and Research

RSS

Recurrence unlikely in childhood cryptogenic stroke

Children with cryptogenic stroke, including that associated with previous varicella infection, are very unlikely to have a recurrence, report researchers.

11 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Pomalidomide safe and effective in treating multiple myeloma

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality

A new American Cancer Society study finds a strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality. The authors say people who drank more than four cups of caffeinated coffee per day were at about half the risk of death of these often fatal cancers compared to those who only occasionally or who never drank coffee.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Saliva increases protective potential during periodontitis

Two constituents of saliva that form part of the defense mechanism of the oral cavity increase during periodontitis, and decrease again after treatment for the condition, study findings show.

10 Dec 2012

Rehabilitation helps restore erectile function post radical prostatectomy

Results from a study published in BJU International indicate that penile rehabilitation programs can help restore erectile function following nerve-sparing robot-assisted radical prostatectomy.

10 Dec 2012

Contrast agent ‘not recommended’ in premature neonates

Premature neonates who are given oral Gastrografin immediately after birth do not pass meconium more quickly than others, study findings suggest.

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

The pharmaceutical industry is experiencing a massive paradigm shift as the era of the highly profitable blockbusters comes to a close. In an attempt to remain competitive, companies are under more pressure than ever to push novel compounds through the development pipeline and so it has been largely left to those in formulation and delivery to optimise their product portfolio using winning business strategies and leading technologies.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Mesupron could extend progression-free survival for metastatic breast cancer patients

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron- is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system.

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

Oral News and Research

Recurrence unlikely in childhood cryptogenic stroke

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Pomalidomide safe and effective in treating multiple myeloma

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Research unveils key gaps in continuity of care for sickle cell patients

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Saliva increases protective potential during periodontitis

Rehabilitation helps restore erectile function post radical prostatectomy

Contrast agent ‘not recommended’ in premature neonates

New hope for leukemia patients

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

Ibrutinib may effectively combat chronic lymphocytic leukemia

Mesupron could extend progression-free survival for metastatic breast cancer patients

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News